Journal article
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy
Leukemia, v 33(9), pp 2266-2275
01 Sep 2019
PMID: 30858549
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
The introduction of CD38-targeting monoclonal antibodies (CD38 MoABs), daratumumab and isatuximab, has significantly impacted the management of patients with multiple myeloma (MM). Outcomes of patients with MM refractory to CD38 MoABs have not been described. We analyzed outcomes of 275 MM patients at 14 academic centers with disease refractory to CD38 MoABs. Median interval between MM diagnosis and refractoriness to CD38 MoAB (T-0) was 50.1 months. The median overall survival (OS) from T o for the entire cohort was 8.6 [95% C.I. 7.5-9.9] months, ranging from 11.2 months for patients not simultaneously refractory to an immunomodulatory (IMiD) agent and a proteasome inhibitor (PI) to 5.6 months for "pentarefractory" patients (refractory to CD38 MoAB, 2 PIs and 2 IMiDs). At least one subsequent treatment regimen was employed after T-0 in 249 (90%) patients. Overall response rate to first regimen after T-0 was 31% with median progression-free survival (PFS) and OS of 3.4 and 9.3 months, respectively. PFS was best achieved with combinations of carfilzomib and alkylator (median 5.7 months), and daratumumab and IMiD (median 4 5 months). Patients with MM refractory to CD38 MoAB have poor prognosis and this study provides benchmark for new therapies to be tested in this population.
Metrics
Details
- Title
- Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy
- Creators
- Ujjawal H. Gandhi - Vanderbilt University Medical CenterRobert F. Cornell - Vanderbilt University Medical CenterArjun Lakshman - Mayo Clinic in ArizonaZhubin J. Gahvari - University of Wisconsin–MadisonElizabeth McGehee - The University of Texas Southwestern Medical CenterMegan H. Jagosky - Levine Cancer InstituteRidhi Gupta - Cancer Prevention Institute of CaliforniaWilliam Varnado - University of Alabama at BirminghamMark A. Fiala - Washington University in St. LouisSaurabh Chhabra - Medical College of WisconsinEhsan Malek - University Hospitals Seidman Cancer CenterJoshua Mansour - Medical University of South CarolinaBarry Paul - Duke UniversityAlyssa Barnstead - Oregon Health & Science UniversitySaranya Kodali - University of VermontAmarendra Neppalli - Medical University of South CarolinaMichaela Liedtke - Stanford Cancer InstituteSwapna Narayana - Medical College of WisconsinKelly N. Godby - University of Alabama at BirminghamYubin Kang - Duke UniversityAnkit Kansagra - The University of Texas Southwestern Medical CenterElvira Umyarova - University of VermontEmma C. Scott - Oregon Health & Science UniversityParameswaran Hari - Medical College of WisconsinRavi Vij - Washington University in St. LouisSaad Z. Usmani - Levine Cancer InstituteNatalie S. Callander - University of Wisconsin–MadisonShaji K. Kumar - Mayo Clinic in ArizonaLuciano J. Costa - University of Alabama at Birmingham
- Publication Details
- Leukemia, v 33(9), pp 2266-2275
- Publisher
- Springer Nature
- Number of pages
- 10
- Grant note
- P30 CA091842 / NCI NIH HHS; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI) P30CA091842 / NATIONAL CANCER INSTITUTE; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- General Internal Medicine
- Web of Science ID
- WOS:000484399300011
- Scopus ID
- 2-s2.0-85062828886
- Other Identifier
- 991022059919004721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
Highly Cited Paper
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Hematology
- Oncology